FI963674A0 - Yhdistelmä-DNA-adenoviruksia, jotka koodittavat aivoperäistä neurotrofista tekijää (BDNF) - Google Patents

Yhdistelmä-DNA-adenoviruksia, jotka koodittavat aivoperäistä neurotrofista tekijää (BDNF)

Info

Publication number
FI963674A0
FI963674A0 FI963674A FI963674A FI963674A0 FI 963674 A0 FI963674 A0 FI 963674A0 FI 963674 A FI963674 A FI 963674A FI 963674 A FI963674 A FI 963674A FI 963674 A0 FI963674 A0 FI 963674A0
Authority
FI
Finland
Prior art keywords
bdnf
recombinant dna
neurotrophic factor
derived neurotrophic
adenovirus encoding
Prior art date
Application number
FI963674A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963674A (fi
Inventor
Pascal Barneoud
Pia Delaere
Michel Perricaudet
Laurent Pradier
Emmanuelle Vigne
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI963674A publication Critical patent/FI963674A/fi
Publication of FI963674A0 publication Critical patent/FI963674A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI963674A 1994-03-18 1996-09-17 Yhdistelmä-DNA-adenoviruksia, jotka koodittavat aivoperäistä neurotrofista tekijää (BDNF) FI963674A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9403191A FR2717496B1 (fr) 1994-03-18 1994-03-18 Virus recombinants, préparation et utilisation en thérapie génique.
PCT/FR1995/000250 WO1995025804A1 (fr) 1994-03-18 1995-03-02 Adenovirus recombinants codant pour le facteur neurotrophique derive du cerveau (bdnf)

Publications (2)

Publication Number Publication Date
FI963674A FI963674A (fi) 1996-09-17
FI963674A0 true FI963674A0 (fi) 1996-09-17

Family

ID=9461190

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963674A FI963674A0 (fi) 1994-03-18 1996-09-17 Yhdistelmä-DNA-adenoviruksia, jotka koodittavat aivoperäistä neurotrofista tekijää (BDNF)

Country Status (12)

Country Link
EP (1) EP0750676A1 (xx)
JP (1) JPH09510358A (xx)
KR (1) KR970701784A (xx)
AU (1) AU703793B2 (xx)
CA (1) CA2184200A1 (xx)
FI (1) FI963674A0 (xx)
FR (1) FR2717496B1 (xx)
IL (1) IL112992A0 (xx)
MX (1) MX9603490A (xx)
NO (1) NO963559L (xx)
WO (1) WO1995025804A1 (xx)
ZA (1) ZA952244B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
DE60137414D1 (de) * 2000-05-05 2009-03-05 Univ City Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
US20210079050A1 (en) * 2018-02-20 2021-03-18 Carmel Haifa University Economic Corporation Ltd. Compositions and methods for delivery and expression of small inhibitory peptides and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755682A1 (en) * 1991-07-10 1997-01-29 Regeneron Pharmaceuticals, Inc. Methods of treatment of motor neuron diseases using members of the BDNF/NT-3/NGF family of molecules
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
WO1994008026A1 (en) * 1992-09-25 1994-04-14 Rhone-Poulenc Rorer S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.

Also Published As

Publication number Publication date
ZA952244B (en) 1996-01-16
FI963674A (fi) 1996-09-17
FR2717496B1 (fr) 1996-04-12
AU1896295A (en) 1995-10-09
WO1995025804A1 (fr) 1995-09-28
EP0750676A1 (fr) 1997-01-02
MX9603490A (es) 1997-03-29
FR2717496A1 (fr) 1995-09-22
IL112992A0 (en) 1995-06-29
JPH09510358A (ja) 1997-10-21
AU703793B2 (en) 1999-04-01
CA2184200A1 (fr) 1995-09-28
KR970701784A (ko) 1997-04-12
NO963559L (no) 1996-08-26

Similar Documents

Publication Publication Date Title
ATE191146T1 (de) Rekombinanten faktor viii enthaltendes stabilisiertes albuminfreies präparat mit niedrigem zuckergehalt
GB2347930B (en) IGF-1 receptor interacting proteins (IIPs), genes coding therefor and uses thereof
BR9709297A (pt) Controlador de falta de bombeamento
EE04684B1 (et) Moraxella catarrhalis v„lismembraani proteiin-106polpeptiid, geenij„rjestus ja selle kasutamine
FI924091A0 (fi) Autoriseringsprotokoll som foersiktighetshjaelpmedel.
HK1033149A1 (en) Disulfide cross-linking glycoprotein hormone analogs, and their preparation and use.
DE69310280D1 (de) Aluminiumoxid-, Calciumoxid-, Yttriumoxid-Dichtungsmittel-Zusammensetzung
FI963674A0 (fi) Yhdistelmä-DNA-adenoviruksia, jotka koodittavat aivoperäistä neurotrofista tekijää (BDNF)
AU1381299A (en) Novel genes encoding transporter-like molecules
TR199500915A2 (tr) Peptidler.
NO973422D0 (no) Recombinant C140-reseptor, dens agonister og antagonister og nukleinsyrer som koder for reseptoren
NL1009152A1 (nl) Aromatische polysulfonharssamenstelling.
DE59712799D1 (de) Aav-dna mit helfervirus-sequenzen
NO901434L (no) Neurotrofiske peptider.
EP0958304A4 (en) NUCLEOTIDE SEQUENCE ENCODING PROTEIN TYPE CD33
DE59813562D1 (de) Pigmentzubereitungen für das Ink-Jet-Verfahren
DE69738977D1 (de) Neues fusionsprotein, dafuer kodierendes gen, rekoerwendung
NO20022542L (no) DNA som koder for et nytt Ets-polypeptid
AU5999099A (en) Dnas encoding novel polypeptides
GB9606983D0 (en) Ultra-violet (u.v) bubble mix
FI884556A (fi) Rekombinantplasmid-dna ppr-ifn 1-13, som kodas foer syntes av maenniskans fibroblast- 1-interferon, foerfarande foer framstaellning daerav och e.coli innehaollande detta.
ITPD970057A0 (it) Carrello per randa
EP1251171A4 (en) NOVEL ENDOPLASMIC PROTEIN WITH LOCALIZED RETICULUM, REMEDIES CONTAINING THIS PROTEIN FOR DISEASES ASSOCIATED WITH GLYCOPROTEIC ANOMALY, DNA ENCODING SAME, AND GENETIC REMEDIES CONTAINING THIS DNA FOR THE TREATMENT OF DISEASES ASSOCIATED WITH GLOBAL ANOMALY
SE9401043D0 (sv) Hamnar (Bassänger), rening, cirk., uppvärmning
IL140030A0 (en) Polypeptides dna molecules encoding them

Legal Events

Date Code Title Description
MA Patent expired